ArticleArchives of osteoporosis2026
Development of a gender score and its association with treatment outcomes in fragility fracture patients screened through Ontario's Fracture Screening and Prevention Program.
Article in Archives of osteoporosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We developed and validated a gender score using data from Ontario's Fracture Screening and Prevention Program and assessed its association with treatment outcomes. Individuals with higher scores exhibited female-like characteristics and were more likely to receive medication prescriptions in the program. Tailored interventions addressing both sex and gender are needed to improve post-fracture care outcomes within the program. PURPOSE: To develop and validate a gender score using data from Ontario's Fracture Screening and Prevention Program (FSPP) and to evaluate its association with treatment outcomes, including medication prescription and initiation, in patients at high risk for future fractures.
methodsA retrospective cohort study was conducted to examine the association between gender score and treatment outcomes in high risk patients who were screened through the FSPP between July 1, 2017, and June 30, 2023. A gender score was constructed using a propensity scoring method, with sex serving as the dependent variable in a multivariable logistic regression model. The gender-related variables were identified from the FSPP dataset. The study also evaluated the face and construct validity of the derived gender score. Multivariable logistic regression was conducted to examine the association between the derived gender score and treatment outcomes.
resultsAmong the 45,135 patients screened through the FSPP, 19,278 patients had complete data for gender-related variables included in the derivation of a gender score. Seven out of eight gender-related variables were found to have associations with sex. The derived gender score demonstrated moderate predictive accuracy, with higher scores indicating higher feminine characteristics. Patients with higher feminine characteristics were significantly more likely to receive a medication prescription within the program.
conclusionWe applied and validated a method to create a gender score using FSPP data and validated the score by demonstrating both face and construct validity. The findings of this study highlight the importance of considering gender-related variables in healthcare delivery, particularly within secondary fracture prevention programs. By examining the influence of gender on treatment outcomes, this study provides valuable insights for developing tailored interventions that address the diverse needs of patients and improve overall care and long-term outcomes.
Indexed as
Identifiers
41961397What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.